3 results
Primary objective:To observe an increase in Overall Response Rate (ORR) from 20% in the pembrolizumab alone arm to 50% in the pembrolizumab after SBRT arm at 12 weeks. Secondary Objective: - Disease Control Rate, defined as the percentage of…
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…
The primary objective is to determine the diagnostic accuracy of the automated diagnostic software (mPDia, Heuron) using SMWI to distinguish neurodegenerative parkinsonism from patients with non-neurodegenerative parkinsonism compared with the final…